Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
14-17 February, 2026
Suppliers Night ExpoSuppliers Night Expo
Not Confirmed
Not Confirmed
16-17 February, 2026
Not Confirmed
Not Confirmed
17-18 February, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
14-17 February, 2026
Suppliers Night ExpoSuppliers Night Expo
Industry Trade Show
Not Confirmed
16-17 February, 2026
Industry Trade Show
Not Confirmed
17-18 February, 2026
Digital content

29 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/29/3228229/0/en/Study-Results-of-Novel-TYK2-Inhibitor-Soficitinib-in-Patients-with-AD-Published-by-JAMA-Dermatology.html

27 Dec 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/clinical-trials/innocare-pharma-gets-green-light-for-phase-ii-trial-of-oral-lupus-drug-18685

17 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/18/3207397/0/en/InnoCare-Announces-Approval-of-Phase-II-III-Clinical-Trial-of-Novel-TYK2-Inhibitor-Soficitinib-for-Chronic-Spontaneous-Urticaria-in-China.html

15 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/15/3205293/0/en/Zenas-BioPharma-s-Partner-InnoCare-Pharma-Announces-Achievement-of-Primary-Endpoint-in-Phase-2b-Study-of-Orelabrutinib-a-BTK-Inhibitor-for-Systemic-Lupus-Erythematosus.html

14 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/14/3205022/0/en/InnoCare-Announces-Achievement-of-Primary-Endpoint-in-Phase-IIb-Study-of-Orelabrutinib-for-SLE-and-Approval-of-Phase-III-Clinical-Trial.html

11 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/11/3203741/0/en/InnoCare-Announces-Approval-of-the-Next-Generation-TRK-Inhibitor-Zurletrectinib-in-China.html
ABOUT THIS PAGE